AbbVie Inc. (NYSE: ABBV) announced that its investigational ABBV‑466, a novel dual‑targeting therapy against IL‑23 p19 and integrin α4β7, demonstrated higher rates of endoscopic remission at Week 12 than either monotherapy in patients with moderate to severe Crohn’s disease (CD) in the ongoing TARGET‑CD Phase 2a platform study.
Study Snapshot
| Item | Detail |
|---|---|
| Sponsor | AbbVie Inc. (NYSE: ABBV) |
| Candidate | ABBV‑466 – dual IL‑23 p19 / integrin α4β7 targeting therapy |
| Study | TARGET‑CD – open‑label, treat‑through Phase 2a platform study |
| Population | 300 patients with moderately to severely active Crohn’s disease, across the spectrum of disease severity and prior treatment experience |
| Treatment Arms | Anti‑IL‑23 p19 monotherapy (risankizumab, n = 94); anti‑α4β7 monotherapy (trosunilimab, n = 100); ABBV‑466 (n = 106) |
| Primary Endpoint | Endoscopic remission at Week 12 |
| Status | Ongoing; Week 24 improvement also reported |
Drug Profile & Mechanism of Action
- Molecule: ABBV‑466, an investigational dual‑targeting biologic under Phase 2a evaluation.
- Targets: Simultaneously engages IL‑23 p19 (a key cytokine subunit driving intestinal inflammation) and integrin α4β7 (a gut‑homing lymphocyte receptor), combining mechanisms previously delivered only as separate agents.
- Comparators: Benchmarked head‑to‑head against risankizumab (anti‑IL‑23 p19 monotherapy) and trosunilimab (anti‑α4β7 monotherapy) within a single platform study.
- Translational Signal: Gene expression analyses showed ABBV‑466 drove colonic epithelial repair and barrier restoration at Week 12, followed by tissue remodeling and metabolic changes at Week 24 — effects generally not observed with either monotherapy.
Clinical Evidence – TARGET‑CD Phase 2a Study
| Endpoint | ABBV‑466 | Risankizumab (anti‑IL‑23 p19) | Trosunilimab (anti‑α4β7) | Relative Benefit |
|---|---|---|---|---|
| Endoscopic Remission – Week 12 (primary) | 30.2 % | 21.3 % | 18.0 % | +8.9 ppt vs. risankizumab; +12.2 ppt vs. trosunilimab |
| Endoscopic Remission – Week 24 | 40.5 % | 22.4 % | 20.0 % | +18.1 ppt vs. risankizumab; +20.5 ppt vs. trosunilimab |
The open‑label, treat‑through study enrolled 300 patients with moderately to severely active Crohn’s disease spanning the full spectrum of disease severity and prior treatment experience. ABBV‑466 met the primary endpoint of endoscopic remission at Week 12, with the separation from both monotherapy arms widening further at Week 24 (40.5 % vs. 22.4 % and 20.0 %), suggesting deepening mucosal healing with continued treatment.
Market Impact & Outlook
- First‑in‑Class Dual Mechanism: By fusing the two most validated anti‑inflammatory targets in IBD into a single agent, ABBV‑466 positions AbbVie to extend its franchise beyond Skyrizi (risankizumab) and defend share in the crowded Crohn’s disease landscape.
- Mucosal Healing as Differentiator: Endoscopic remission is the anchor endpoint regulators and payers increasingly emphasize; a near‑doubling of Week 24 remission versus both monotherapies is a clinically meaningful signal for severe and refractory patients.
- Tissue Repair Biology: The gene expression data pointing to epithelial repair, barrier restoration, and tissue remodeling may support a disease‑modifying narrative that single‑target biologics have struggled to establish.
- Pipeline Strategy: TARGET‑CD’s platform design allows AbbVie to benchmark combination versus monotherapy internally, informing Phase 3 dose, duration, and positioning decisions. Further readouts and pivotal‑trial plans were not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the clinical development, regulatory pathways, and commercial potential of ABBV‑466. As an investigational product in an early‑phase, open‑label study, ABBV‑466’s safety and efficacy are not fully established; no regulatory agency has approved it for any indication. Actual results may differ materially due to clinical trial outcomes, competitive dynamics, and regulatory requirements.-Fineline Info & Tech
